Overview
NICE was unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor mutation-positive non-small-cell lung cancer. This is because Roche did not provide an evidence submission
Last reviewed: 22 March 2017
Next review: We will review this decision if the company decides to make a submission.